US-headquartered contract research organization, Omnicare Clinical Research has opened new offices in Shanghai and Beijing. The fully staffed facilities include professionals for project management, clinical trial services, regulatory affairs and business development.
According to Dr Dale Evans, President and CEO of Omnicare, the opening of Shanghai and Beijing offices represents a vital component of Omnicare's Asia Pacific business strategy. The region is a promising center of drug development that offers numerous advantages.
Since 2001, Omnicare has had a strong presence in China. The company's other offices in the Asia Pacific region include Australia, India, Japan, Singapore and Taiwan.
Omnicare is a major phase I to IV globally focused contract research organization serving the biopharmaceutical and medical device industries.